Rapid detection of bacteria in patients with spine and heart infections
Direct Detection of ESKAPE Pathogens From Whole Blood Using T2MR Bacteria Panel in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis
This study is testing a new method to quickly find the bacteria causing spine and heart infections in patients to help them get the right treatment faster.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Charles University, Czech Republic Academic / other |
| Locations | 1 site (Prague) |
| Trial ID | NCT05644990 on ClinicalTrials.gov |
What this trial studies
This observational study aims to quickly identify the bacterial causes of pyogenic spondylodiscitis and infective endocarditis using the T2 Bacteria Panel, which employs polymerase chain reaction (PCR) and T2 magnetic resonance technology. By analyzing whole blood samples, the study focuses on detecting six specific pathogens known as ESKAPE. The goal is to achieve faster and more accurate results compared to traditional blood culture methods, potentially leading to quicker and more effective treatment for patients. The study builds on previous successful applications of the T2 Bacteria Panel in bloodstream infections.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with spondylodiscitis or infective endocarditis who have not received antibiotics for more than 24 hours.
Not a fit: Patients with unconfirmed infections or those who have been on antibiotics for longer than 24 hours may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the time to diagnosis and improve treatment outcomes for patients with serious infections.
How similar studies have performed: Previous studies using the T2 Bacteria Panel have shown promising results in detecting pathogens in bloodstream infections, suggesting potential success for this approach in localized infections.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of spondylodiscitis or/and facet joint infection or/and sacroileitis * Diagnosis of infective endocarditis * Antibiotic treatment not received or not longer than 24 hours * Ability to give informed consent Exclusion Criteria: * Spine infection or/and endocarditis not confirmed * Antibiotic treatment longer than 24 hours * Inability to give informed consent
Where this trial is running
Prague
- University Hospital Bulovka — Prague, Czechia (Recruiting)
Study contacts
- Study coordinator: Lucie Cíchová, MD
- Email: lucie.cichova@protonmail.com
- Phone: +420728781647
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.